Advertisement

Bulletin of Experimental Biology and Medicine

, Volume 145, Issue 6, pp 696–699 | Cite as

Myocardial resistance to ischemic and reperfusion injuries under conditions of chronic administration of opioid receptor agonists and antagonists

  • Yu. B. Lishmanov
  • D. L. Stakheev
  • A. V. Krylatov
  • N. V. Naryzhnaya
  • L. N. MaslovEmail author
  • M. V. Ovchinnikov
  • F. Kolar
Article

Abstract

Chronic treatment with opioid receptor ligands: nonselective peptide opioid receptor agonist dalargin (intraperitoneally in a dose of 1 mg/kg), selective nonpeptide κ-receptor agonist GR 89696 (subcutaneously in a dose of 0.03 mg/kg), nonselectrive nonpeptide antagonist quadazocine (subcutaneously in a dose of 3 mg/kg) or naltrexone (subcutaneously in a dose of 10 mg/kg) for 20 day had no effect of the incidence of ischemic ventricular arrhythmias and the size of necrotic zone after coronary occlusion and reperfusion in rats in vivo.

Key Words

chronic treatment with opioid receptor agonists myocardium ischemia reperfusion 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    A. G. Gorgaslidze, M. A. Saifulaeva, M. M. Kuz'mina, et al., Kardiologiya, No. 1, 14–16 (1993).Google Scholar
  2. 2.
    N. V. Korobov, Farmakol. Toksikol., No. 4, 35–38 (1988).Google Scholar
  3. 3.
    Yu. B. Lishmanov, L. N. Maslov, and K. Rais, Eksp. Klin. Farmakol., 65, No. 4, 71–77 (2002).PubMedGoogle Scholar
  4. 4.
    L. N. Maslov, E. I. Barzakh, A. A. Platonov, et al., Byull. Eksp. Biol. Med., 140, No. 12, 633–638 (2005).Google Scholar
  5. 5.
    P. J. Birch, H. Rogers, A. G. Hayes, et al., Br. J. Pharmacol., 103, No. 3, 1819–1823 (1991).PubMedGoogle Scholar
  6. 6.
    E. R. Butelman, M. C. Holden, O. Ko, et al., J. Pharmacol. Exp. Ther., 298, No. 3, 1049–1059 (2001).PubMedGoogle Scholar
  7. 7.
    M. Y. Chan, S. Dai, and W. W. Ko, Br. J. Pharmacol., 90, No. 3, 537–543 (1987).PubMedGoogle Scholar
  8. 8.
    L. A. Dykstra, D. E. Gmerek, G. Winger, and J. H. Woods, J. Pharmacol. Exp. Ther., 242, No. 2, 421–427 (1987).PubMedGoogle Scholar
  9. 9.
    C. Ela, J. Barg, Z. Vogel, et al., J. Mol. Cell. Cardiol., 29, No. 2, 711–720 (1997).PubMedCrossRefGoogle Scholar
  10. 10.
    S. S. Negus, T. F. Burke, F. Medzihradsky, and J. H. Woods, J. Pharmacol. Exp. Ther., 267, No. 2, 896–903 (1993).PubMedGoogle Scholar
  11. 11.
    J. N. Peart, E. R. Gross, and G. J. Gross, J. Cardiovasc. Pharmacol., 43, No. 3, 410–415 (2004).PubMedCrossRefGoogle Scholar
  12. 12.
    J. E. Schultz, A. K. Hsu, and G. J. Gross, J. Mol. Cell. Cardiol., 29, No. 8, 2187–2195 (1997).PubMedCrossRefGoogle Scholar
  13. 13.
    J. E. Schultz, Y. Z. Qian, G. J. Gross, and R. C. Kukreja, Ibid., No. 3, pp. 1055–1060.Google Scholar
  14. 14.
    R. Tao, M. Karnik, Z. Ma, and S. B. Auerbach, Br. J. Pharmacol., 139, No. 8, 1498–1504 (2003).PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2008

Authors and Affiliations

  • Yu. B. Lishmanov
    • 1
  • D. L. Stakheev
    • 1
  • A. V. Krylatov
    • 1
  • N. V. Naryzhnaya
    • 1
  • L. N. Maslov
    • 2
    Email author
  • M. V. Ovchinnikov
    • 2
  • F. Kolar
    • 3
  1. 1.Laboratory of Experimental Cardiology, Institute of Cardiology, Tomsk Research CenterSiberian Division of Russian Academy of Medical SciencesSiberianRussia
  2. 2.Laboratory of Peptide Synthesis, Russian Cardiology Research_and Production ComplexFederal Agency for Health Care and Social DevelopmentSiberianRussia
  3. 3.Department of Evolution Cardiology, Institute of PhysiologyCzech Academy of SciencesPragueCzechoslovakia

Personalised recommendations